Patents Represented by Attorney Hoxie and Associates LLC
-
Patent number: 8338144Abstract: The present invention discloses an isolated polynucleotide molecule derived from a polynucleotide encoding a polypeptide having L-sorbosone dehydrogenase activity comprising a partial nucleotide sequence of at least 20 consecutive nucleotides of SEQ ID NO:1. The present invention further relates to a process for the production of L-ascorbic acid in high yield, in particular a process using resting cells of a microorganism able to convert given carbon sources into vitamin C. The thus obtained vitamin C may be further processed by purification and/or separation steps.Type: GrantFiled: February 8, 2010Date of Patent: December 25, 2012Assignee: DSM IP Assets B.V.Inventors: Alan Berry, Connie Lee, Anne Françoise Mayer, Masako Shinjoh
-
Patent number: 8337842Abstract: The invention provides heterochimeric antibodies and/or fragments thereof comprising (i) hypervariable region sequences wholly or substantially corresponding to sequences found in antibodies from a donor species; (ii) constant region sequences wholly or substantially corresponding to sequences found in antibodies from a target species which is different from the donor species; and (iii) heavy and/or light chain variable framework sequences which contain at least three non-CDR residues corresponding to sequences found in antibodies from a target species and at least three contiguous non-CDR residues corresponding to sequences found in antibodies from a donor species. The invention further provides antibody to canine or feline or equine antigens, e.g., CD20 or CD52, and methods of making and using antibodies as described.Type: GrantFiled: September 4, 2009Date of Patent: December 25, 2012Assignee: Vet Therapeutics, Inc.Inventor: Geneviève Hansen
-
Patent number: 8329706Abstract: The present invention relates to oxazolidinone derivatives of formula (I) wherein Y, R3 and R4 are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as orexin receptor antagonists.Type: GrantFiled: May 11, 2010Date of Patent: December 11, 2012Assignee: Actelion Pharmaceuticals Ltd.Inventors: Hamed Aissaoui, Christoph Boss, Christine Brotschi, Markus Gude, Romain Siegrist, Thierry Sifferlen, Jodi T Williams
-
Patent number: 8329242Abstract: A process for producing a chocolate or chocolate-like product comprises: (i) mixing a part of the components of the chocolate or chocolate-like product to form a mixture; (ii) homogenizing the mixture with fat using a rotor/stator homogenizer; and (iii) conching the homogenized mixture.Type: GrantFiled: July 17, 2008Date of Patent: December 11, 2012Assignee: Barry Callebaut AGInventors: Luc Joseph Paul Antonie Marie Rumbaut, Rik Jan Theo Weetjens
-
Patent number: 8329243Abstract: A process for producing chocolate or a chocolate-like product comprises: (i) forming a first mixture comprising components of the chocolate or chocolate-like product; (ii) grinding the first mixture in first grinding means; (iii) forming a second mixture comprising components of the chocolate or chocolate-like product; (iv) grinding the second mixture in second grinding means different from the first grinding means; (v) combining the first and second mixtures to form a third mixture; and (vi) conching the third mixture to form the chocolate or chocolate-like product.Type: GrantFiled: July 17, 2008Date of Patent: December 11, 2012Assignee: Barry Callebaut AGInventor: Luc Joseph Paul Antonie Marie Rumbaut
-
Patent number: 8324232Abstract: The invention relates to the compound of structural formula (I) and the salts thereof. Said compound is useful as endothelin receptor antagonist. The invention further relates to a process for preparing said compound.Type: GrantFiled: August 15, 2008Date of Patent: December 4, 2012Assignee: Actelion Pharmaceuticals Ltd.Inventors: Martin Bolli, Christoph Boss, Alexander Treiber
-
Patent number: 8318802Abstract: This invention relates to a stable epoprostenol composition that can be combined with commercially available IV fluids and can be administered in its reconstituted and/or diluted form under ambient conditions of about 15-30° C. for greater than 24 hours. The composition preferably contains (a) epoprostenol or a salt thereof; (b) a alkalinization agent; and (c) a base, such that when reconstituted or in solution, the solution has a pH>11. Methods for making the lyophilized composition are also disclosed.Type: GrantFiled: February 2, 2007Date of Patent: November 27, 2012Assignee: Actelion Pharmaceuticals Ltd.Inventor: Naglesh R. Palepu
-
Patent number: 8314238Abstract: The present invention relates to a process for the preparation of the compound of formula (7) which process comprises the hydrogenation of the compound of formula (4) using bis[chloro-1,5-cyclooctadiene-iridium], (S)-i-dicyclohexylphosphino-2-[(S)-?-(dimethylamino)-2-(dicyclohexylphosphino)benzyl]-ferrocene as a catalyst.Type: GrantFiled: December 23, 2008Date of Patent: November 20, 2012Assignee: Actelion Pharmaceuticals Ltd.Inventors: Erhard Bappert, Andreas Hendrikus Maria De Vries, Doris Domin, Matthias Helms, Christoph Imboden, Zarghun Nazir, Wolfgang Skranc, Felix Spindler, Michael Stanek, Wilhelm Tschebull, Gerardus Karel Maria Verzijl
-
Patent number: 8314253Abstract: The invention relates to compounds of formula (I) wherein R1, R2, R3, R4, A, B, W and n are as defined in the description, and to pharmaceutically acceptable salts of such compounds. These compounds are useful as calcium channel blockers.Type: GrantFiled: October 21, 2009Date of Patent: November 20, 2012Assignee: Actelion Pharmaceuticals Ltd.Inventors: Kurt Hilpert, Francis Hubler, Dorte Renneberg
-
Patent number: 8309126Abstract: The invention relates to dispersible tablets comprising the compound 4-tert-butyl-N-[6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(pyrimidin-2-yl)-pyrimidin-4-yl]-benzenesulfonamide.Type: GrantFiled: June 7, 2011Date of Patent: November 13, 2012Assignee: Actelion Pharmaceuticals, Ltd.Inventors: Lovelace Holman, Timm Trenktrog
-
Patent number: 8309722Abstract: The present invention provides methods for the preparation of substituted heterocycle fused gamma-carbolines, intermediates useful in producing them and methods for producing such intermediates and such heterocycle fused gamma-carbolines.Type: GrantFiled: March 12, 2008Date of Patent: November 13, 2012Assignee: Intra-Cellular Therapies, Inc.Inventors: John Charles Tomesch, Peng Li, Wei Yao, Qiang Zhang, James David Beard, Andrew S. Thompson, Hua Cheng
-
Patent number: 8298605Abstract: A process for producing a chocolate or chocolate-like product comprising: (i) dry grinding a mixture of solid components of chocolate or a chocolate-like product; and (ii) homogenizing the ground mixture with fat to form a liquid chocolate or chocolate-like product.Type: GrantFiled: July 17, 2008Date of Patent: October 30, 2012Assignee: Barry Callebaut AGInventors: Luc Joseph Paul Antonie Marie Rumbaut, Rik Jan Theo Weetjens
-
Patent number: 8299086Abstract: The invention relates to novel pyrimidine derivatives, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunomodulating agents.Type: GrantFiled: October 31, 2008Date of Patent: October 30, 2012Assignee: Actelion Pharmaceuticals Ltd.Inventors: Martin Bolli, Cyrille Lescop, Boris Mathys, Claus Mueller, Oliver Nayler, Beat Steiner
-
Patent number: 8288411Abstract: The invention relates to compounds of formula (I) wherein Y, A, N and R1 are as described in the description, to salts, especially pharmaceutically acceptable salts, of such compounds and to the use of such compounds as medicaments, especially as orexin receptor antagonists.Type: GrantFiled: September 23, 2008Date of Patent: October 16, 2012Assignee: Actelion Pharmaceuticals Ltd.Inventors: Hamed Aissaoui, Christoph Boss, Ralf Koberstein, Thierry Sifferlen
-
Patent number: 8288435Abstract: The invention relates to novel 2-aza-bicyclo[3.1.0]hexane derivatives of Formula (I) wherein A, B, n and R1 are as described in the description, and to the use of such compounds, or of pharmaceutically acceptable salts of such compounds, as medicaments, especially as orexin receptor antagonists.Type: GrantFiled: December 28, 2007Date of Patent: October 16, 2012Assignee: Actelion Pharmaceuticals Ltd.Inventors: Hamed Aissaoui, Christoph Boss, Markus Gude, Ralf Koberstein, Thierry Sifferlen, Daniel Trachsel
-
Patent number: 8288429Abstract: The invention relates to 2-aza-bicyclo[3.3.0]octane derivatives of Formula (I) wherein A, B, and R1 are as described in the description, and to the use of such compounds, or of pharmaceutically acceptable salts of such compounds, as medicaments, especially as orexin receptor antagonists.Type: GrantFiled: July 25, 2008Date of Patent: October 16, 2012Assignee: Actelion Pharmaceuticals Ltd.Inventors: Hamed Aissaoui, Christoph Boss, Markus Gude, Ralf Koberstein, Thierry Sifferlen, Daniel Trachsel
-
Patent number: 8288385Abstract: The present invention relates to 6-(3-aza-bicyclo[3.1.0]hex-3-yl)-2-phenyl-pyrimidine derivatives and their use as P2Y12 receptor antagonists in the treatment and/or prevention of peripheral vascular, of visceral-, hepatic- and renal-vascular, of cardiovascular and of cerebrovascular diseases or conditions associated with platelet aggregation, including thrombosis in humans and other mammals.Type: GrantFiled: April 7, 2010Date of Patent: October 16, 2012Assignee: Actelion Pharmaceuticals Ltd.Inventors: Eva Caroff, Kurt Hilpert, Francis Hubler, Emmanuel Meyer, Dorte Renneberg
-
Patent number: 8288554Abstract: The invention relates to pyridin-3-yl derivatives of Formula (I) wherein R1, R2, R3, R4, R5; R6 and A are as described in the description, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunomodulating agents.Type: GrantFiled: September 6, 2007Date of Patent: October 16, 2012Assignee: Actelion Pharmaceuticals Ltd.Inventors: Martin Bolli, David Lehmann, Boris Mathys, Claus Mueller, Oliver Nayler, Beat Steiner, Jörg Velker
-
Patent number: RE43728Abstract: The invention relates to pharmaceutical compositions containing at least one thiazolidin-4-one derivative to prevent or treat disorders associated with an activated immune system. Furthermore, the invention relates to novel thiazolidin-4-one derivatives notably for use as pharmaceutically active compounds. Said compounds particularly act also as immunosuppressive agents.Type: GrantFiled: November 16, 2004Date of Patent: October 9, 2012Assignee: Actelion Pharmaceuticals Ltd.Inventors: Christoph Binkert, Martin Bolli, Boris Mathys, Claus Mueller, Michael Scherz, Oliver Nayler
-
Patent number: RE43833Abstract: The invention relates to pharmaceutical compositions containing at least one thiazolidin-4-one derivative to prevent or treat disorders associated with an activated immune system. Furthermore, the invention relates to novel thiazolidin-4-one derivatives notably for use as pharmaceutically active compounds. Said compounds particularly act also as immunosuppressive agents.Type: GrantFiled: August 9, 2011Date of Patent: November 27, 2012Assignee: Actelion Pharmaceuticals Ltd.Inventors: Christoph Binkert, Martin Bolli, Boris Mathys, Claus Mueller, Michael Scherz, Oliver Nayler